This dynamic big pharma is undergoing a few key changes.One of the world's top biopharma companies, AbbVie (ABBV 1.16%) is a fairly complicated stock to approach as an independent investor. Aside from the scientific chops needed to evaluate the quality of its pipeline and the competitive landscape it operates in, you need to understand a suite of governance and business matters before buying the stock.Let's take a moment and identify three primary areas of interest, so you're better equipped to determine wh ...